SCHEMBL1879719

SCHEMBL1879719

Cc1ccc2cc(COc3cc(C)nc(N)n3)c(-c3ccccc3C)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.39
NUDT1 P36639 3/20 0.39
ADORA2A P29274 1/20 0.38
POLB P06746 1/20 0.38
PIK3CG P48736 2/20 0.38
PIK3C2B O00750 1/20 0.35
HSP90AA1 P07900 1/20 0.34
CTSD P07339 1/20 0.34
BACE1 P56817 1/20 0.34
LMNA P02545 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ESR1 P03372 1/20 0.34
DHFR P00374 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880139 0.87 ALDH1A1 (0.43) NUDT1ADORA2APOLBTDP1KMT2A
SCHEMBL1883116 0.83 KDM4E (0.41) PIK3CDNUDT1ADORA2APOLBPIK3CG
SCHEMBL1886299 0.81 PIK3CD (0.40) PIK3CDNUDT1ADORA2APOLBLMNA
SCHEMBL1877296 0.78 PIK3CD (0.43) PIK3CDNUDT1ADORA2APOLB
SCHEMBL1884555 0.76 PIK3CD (0.44) PIK3CDNUDT1ADORA2APOLBHSP90AA1
SCHEMBL1877264 0.74 KMT2A (0.43) PIK3CDADORA2APOLBPIK3CGCTSD
SCHEMBL1888175 0.74 KMT2A (0.43) PIK3CDADORA2APIK3CGCTSDBACE1
SCHEMBL1883779 0.73 PIK3CD (0.48) PIK3CDNUDT1DHFRATM
SCHEMBL1884713 0.73 PIK3CD (0.46) PIK3CDNUDT1HSP90AA1
SCHEMBL1885095 0.73 PIK3CD (0.40) PIK3CDNUDT1ADORA2APIK3CGLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE PIK3CD 8/4885NUDT1 1761/4885ADORA2A 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.